Triggering memory B cells directly in lungs seen as way to improve vaccines

By The Science Advisory Board staff writers

June 29, 2022 -- How can the efficacy of vaccines used to protect against viral respiratory diseases such as influenza and COVID-19 be increased? The triggering of memory B cells directly in the lungs could be a promising method, according to scientists.

Currently, vaccines are administered intramuscularly and do not trigger the appearance of these cell populations. However, to better understand these cells and their involvement in the long-term immune response against respiratory infections, researchers worked with two mouse models of virus infection: influenza and SARS-CoV-2.

Their research, published in the journal Immunity, showed that about 10 weeks after inoculation of the virus and after its elimination from the body, the formation of groups of memory B cells was observed in the bronchial respiratory mucosa, allowing them to be directly in contact with any new virus entering the lungs.

Researchers see these findings as the basis for a longer-term way of improving the efficacy of influenza and COVID-19 vaccines and new research into the way vaccines are administered.

COVID-19 mRNA-based vaccines benefit from decades of research
25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in...
Technology upgrades needed to address future pandemics, GAO report says
Vaccine R&D and manufacturing face many challenges despite the success of COVID-19 vaccines. This is according to a new U.S. Government Accountability...
Where is the immunotherapy field headed after COVID-19?
WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter